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Aplicações clínicas de imunoglobulina em doenças neuromusculares com foco em
miopatias inflamatórias
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ABSTRACT
During recent years, an increasing number of neuromuscular diseases have been recognized either to be caused primarily by autoimmune
mechanisms, or to have important autoimmune components. The involved pathophysiological mechanisms and clinical manifestations
have been better recognized and many of these disorders are potentially treatable by immunosuppression or by immunomodulation with
intravenous immunoglobulin (IVIg). IVIg has been tried in a variety of immune-mediated neurological diseases, being target of widespread
use in central and peripheral nervous systems diseases. Objective: To give an overview of the main topics regarding the mechanism of
action and different therapeutic uses of IVIg in neurological practice, mainly in neuromuscular diseases.
Keywords: immunoglobulin, neuromuscular diseases, autoimmunity, inflammatory myopathy.
RESUMO
Nos últimos anos, um número progressivo de doenças neuromusculares passaram a ser reconhecidas tanto por ser causadas por
mecanismos autoimunes ou por envolver importantes componentes autoimunes. Os mecanismos fisiopatológicos e as manifestações
clínicas envolvidos têm sido mais bem reconhecidos e muitas de tais doenças são potencialmente tratáveis por imunossupressão ou
imunomodulação com imunoglobulina intravenosa (IVIg). IVIg vem sendo utilizada em uma variedade de doenças neurológicas
imunomediadas, sendo alvo de amplo uso em doenças dos sistemas nervosos central e periférico. Objetivo: Oferecer uma visão global
sobre os principais tópicos relacionados aos mecanismos de ação e aos diferentes usos terapêuticos da IVIg na prática neurológica,
principalmente em doenças neuromusculares.
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The number of inflammatory neurological diseases has
significantly increased in the last decades. The involved
pathophysiological mechanisms and clinical manifestations
have been better recognized and in proportion has been
increasing the number of different therapeutic proposals, not-
ably in the field of immune-mediated neurological diseases.
Old neurological disorders essentially credited as primarily
degenerative and infectious diseases evinced the importance
of its inflammatory and immune-mediated components in its
pathophysiology. Treatments formely used for autoimmune
inflammatory diseases and primary immunodeficiencies
have become frequently used in various neurological diseases
and in a wide different group of contexts, highlighting the
immunomodulatory drugs, corticosteroids, plasmapheresis
and intravenous immunoglobulin (IVIg)1. In this perspective,
the use of IVIg represents an important therapeutic perspect-
ive in large amounts of immune-mediated neurological dis-
eases, being target of widespread use in central and
peripheral nervous systems diseases. The main focus of this
review is to highlight the main mechanisms of action and
current uses of IVIg in neurological practice.
MECHANISMS OF ACTION AND BASIS OF CURRENT
USE OF IMMUNOGLOBULIN
IVIg preparation offers a mix of concentrated formula-
tions of human IgG prepared by industrial fractionation of
different pools of plasma donations with functionally
and structurally intact immunoglobulin and its associated
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antibody profiles. More than 30 different preparations of
intravenous immunoglobulin are currently available for use
in different settings and clinical conditions. In primary and
secondary antibody immunodeficiencies, immunoglobulin
replacement therapy originally required monthly intraven-
ous applications of 400 to 600 mg/kg associated with serum
IgG level controls. Nowadays anti-inflammatory and immu-
nomodulatory actions are commonly observed at higher
doses (400 mg/kg per day, most commonly for 5 days, or
1 g/kg per day for 2 days). This total dose of 2 g/kg is the
most common applied therapeutic strategy to treat different
immunomediated neurological disorders2, since the first
clinical attempts with refractory chronic polymyositis3.
Subcutaneous administration has been also previously used,
temporarily abandoned due to complications from sterile
abscesses in the past, and currently used safely as an alternative
for prophylaxis in primary immunodeficiencies2. It is not well-
established for use in neurological autoimmune diseases.
Drug adverse effects are commonly described affecting
up to 15% of patients with intravenous infusion of immuno-
globulin, generally in a mild early-onset non-anaphylactoid
fashion with nonspecific systemic clinical complaints, includ-
ing headache, drowsiness, tachycardia and hypotension.
Some of theses cases are self-limiting and require the stop or
prompt slowing of immunoglobulin infusion rate or even stop-
page and the use of symptomatic therapy, mainly represented
by corticosteroids, nonsteroidal antiinflammatory drugs and
intravenous hydration. There is also the description of early-
onset severe anaphylaxis commonly associated with IgA defi-
ciency in serum levels lesser than 0.05 g/L. Acute renal failure
(not related to sorbitol-based formulations), sepsis, transient
neutropenia, disseminated intravascular coagulation, hepatitis
C viral and parvovirus B19 infection, Transfusion-associated
Acute Lung Injury (TRALI), aseptic meningitis, thrombotic
events (deep venous thrombosis, pulmonary embolism, acute
myocardial infarction, stroke), pseudohyponatremia and
late-onset arthritis, aseptic meningitis and neurodegeneration
have also been described in related to the use of IVIg2,4.
Although initially applied for patients with specific prim-
ary immunodeficiency diseases, IVIg is widely used now-
adays for different groups of clinical conditions (Table 1),
mainly hematological, dermatological and autoimmune dis-
eases5,6,7,8,9. Despite the seemingly supplementation and pro-
phylatic mechanism involved with its classical use in some
immunodeficiencies, the clinical response observed in differ-
ent contexts of diverse pathophysiological autoimmunity
enabled the development of different hypotheses regarding
the drug’s mechanism of action. This review covers some
of the key mechanisms previously described.
The set of immunomodulatory mechanisms related to the
action of IVIg is variable, complex and not well established,
and there is still controversial points between clinical practice
and experimental studies6. It is also important to emphasize
that the inflammatory activities of immunoglobulin depend
mainly on its concentration, producing paradoxical
responses of pro- and anti-inflammatory actions10. Its uses
comprise different groups of actions mediated via the vari-
able regions Fab ( fragment, antigen-binding region in the
arms of the Y arm) and the direct effect of Fc region ( frag-
ment, crystallizable region in the base of the Y arm), by
complement binding in the Fc region, and by other immuno-
modulatory substances present in the preparations of intra-
venous immunoglobulin6,11. There is direct interaction
between the Fc portion of immunoglobulins with their recep-
tors yielding the well-known immunoregulatory effects. It
also occurs in modulating effector functions and activation
of B and T lymphocytes, neutralization of pathogenic autoan-
tibodies, interference with the process of antigen presenta-
tion and the complement and cytokine-dependent overall
anti-inflammatory effect12. Inhibitory Fc-gamma receptor
FcgammaRIIB, expressed on myeloid cells and B cells, is
required for the anti-inflammatory activity of intravenous
Table 1. Major non-neurological diseases for which intravenous immunoglobulin has been previously used5,6,7,8,9.
Clinical diseases and intravenous immunoglobulin use
Hematologic diseases Idiopathic thrombocytopenic purpura; autoimmune hemolytic anemia; hemolytic disease of the newborn with
severe hyperbilirubinaemia; parvovirus B19-associated aplasia; immune neutropenia; thrombotic
thrombocytopenic purpura; acquired von Willebrand disease; acquired factor VIII inhibitor; prophylaxis (for graft-
versus-host disease and infectious) after bonemarrow transplantation (in recipients older than 20 years of age) and
for B-cell chronic lymphocytic leukaemia
Rheumatologic
diseases
Kawasaki disease, systemic lupus erythematosus (hematological, central and peripheral nervous
system, serositis and renal activities), fibromyalgia
Dermatologic diseases Autoimmune bullous disease (bullous pemphigoid, pemphigus vulgaris and foliaceus, linear IgA
disease), erythema multiforme, toxic epidermal necrolysis, chronic urticaria, pyoderma
gangrenosum, scleromyxedema, atopic dermatitis
Gastroenterological
diseases
Severe Clostridium difficile colitis, inflammatory bowel disease
Primary
immunodeficiencies
Prophylaxis in hypogammaglobulinaemia; severe combined Immunodeficiency; X-linked agammaglobulinaemia,
common variable immunodeficiency disorders, immunodeficiency with hyper-IgM syndrome, Wiskott-Aldrich
syndrome, ataxia-telangiectasia (Louis-Bar syndrome), DiGeorge syndrome, Good syndrome (thymoma with
immunodeficiency), X-linked lymphoproliferative syndrome, hyper-IgE syndrome
Miscellaneous Prophylaxis in children with chronic HIV infection; autoimmune uveitis; Birdshot retinochoroidopathy,
streptococcal toxic schock syndrome, systemic vasculitis, severe drug-induced antibody deficiency
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immunoglobulin13. For example, impaired expression of the
inhibitory FcgammaR in chronic inflammatory demyelinat-
ing polyneuropathy (CIDP) can be partially restored by
immunoglobulin treatment and changing the impaired
late B cell differentiation step checkpoint. In the context of
immunoglobulin’s V-region dependent mechanisms of action,
in the case of medium-sized vessel vasculitis, an important
reduction in serum cytokines levels has been established14.
In the context of the overall anti-inflammatory effect, for
example, it has also been proved that immunoglobulin use
in polymyositis inhibits TNF-alpha, interleucin-1 and the
uptake of C3 for deposition of complement membrane
attack complex on the endomysial capillaries, and also
blocks the process of macrophageal Fc receptor-mediated
phagocytosis15. Other mechanism proposed involving the
immunoglobulin Fc region in dermatomyositis involves
also the binding of C4b14. It is also established new anti-
inflammatory properties of the minor fraction of sialylated
immunoglobulin molecules10.
Furthermore, in addition to the more classical mechan-
isms, recent studies also showed that immunoglobulin pro-
ducts contains specific anti-Tau antibodies, suggesting the
possibility of applying this drug for patients with mild to
moderate Alzheimer’s disease16, although no clinical evid-
ence was obtained from former clinical trials and experi-
mental studies from over a decade17. It is believed, though
mainly hypothetical, that human anti-amyloid-beta anti-
bodies may also play an important role in the clearance of
aggregates of amyloid proteins in the elderly with
Alzheimer’s disease18. Other proposed associated mechanism
of action involves target-site integrins on extracellular matrix
and cell surfaces19, lymphocyte and monocyte apoptosis
induction2, modulation of regulatory Tcells, inhibition of differ-
entiation and maturation of dendritic cells, and apoptosis of B
and T cells using Fas receptor-related pathways20.
IVIG – PREPARATIONS
There are different preparations of IVIg available for use
in clinical practice (Table 2).
Classical and current neurological indications
Its use has been widespread in other specialties than
Neurology (Table 1)5,6,7,8,9, although US Food and Drug
Administration approved the use of IVIg in few conditions,
including Allogeneic bone marrow transplantation, chronic
lymphocytic leukemia, common variable immunodeficiency,
pediatric HIV type I infection, Kawasaki disease, immune-
mediated thrombocytopenia, kidney transplantation (with
high antibody recipiente or with an ABO incompatible
donor), primary immunodeficiency disorders with defects
in humoral immunity and hematopoietic stem cell trans-
plantation (patients older than 20 years). In Brazil, regarding
the autoimmune neurological conditions, the Agência
Nacional de Vigilância Sanitária (ANVISA) approved the use
of IVIg in only five conditions (ANVISA Public Consultation,
number 36, 20/05/2004; and Ministry of Health of Brazil,
Ordinance number 3,439, 11/11/2010): Guillain-Barré syn-
drome, myasthenia gravis, juvenil dermatomyositis, other der-
matomyositis, and polymyositis. Although commonly used
among different neurological contexts (Table 3), immunoglo-
bulin use has been studied in a proper manner in neuro-
muscular disorders2,18,21,22,23,24,25,26. Neuromuscular junction
diseases have been target of studies with different immuno-
modulatory therapies, including the isolated and combined
use of immunoglobulin. In myasthenia gravis, IVIg has its
use approved in cases of rapidly progressive disease (severe
clinical manifestation or in severe exacerbation), myasthenic
crisis (similarly to the plasma exchange), preparation of
patients with weakness for surgeries (including therapeutic
thymectomy) and as adjuvant in cases of chronic oral immu-
nossupressive therapy aiming the reduction of cumulative
dose and minimizing its long-term side effects2,27. There is
no formal indication for chronic maintenance therapy
alone. In other neuromuscular junction disorders, like
Lambert-Eaton myasthenic syndrome, case reports and small
placebo-controlled study indicate the possibility of mild to
moderate improvement in clinical and electroneuromyo-
graphic parameters (mainly the amplitude of the resting
CMAP) in patients refractory to immunossupressive drugs28.
Among all peripheral neuropathy and polyradiculoneuro-
pathy, most studies with promising and positive results with
Table 2. Different preparations of immunoglobulin available and their biochemical and pharmacokinetic properties.
Properties Gammagard Gammar-P Gamunex Octagam Flebogamma
Sandoglobulina
Privigen
Kiovig
Laboratory ARC/Baxter Aventis Bayer Octapharma Grifols CSL Behring Baxter
Form Powder Powder Liquid Liquid Liquid Liquid Liquid
Concentration (%) 5-10 5 10 5 5-10 10 10
Osmolarity 125-636 309 258 310-380 327-342 320 309
IgA (mg/mL) ,2.4 ,25 46 ,0.4 ,0.003 ,0.025 ,0.14
Stabilizer Glucose (20-40 mg) Sucrose (50 mg) None Maltose Sorbitol 5% Proline Sucrose
Salt (mg/mL) 8.5-17 5 Trace 0 ,3.2 ,1 5
Time of infusion (hours) 1.2-5 5-6 2 4-6 3.1 1.2-5 5-6
pH 6.4-7.2 6.4-7.2 4-4.5 5.1-6 5.6 4.8 6.4-7.2
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immunoglobulin involved patients with multifocal motor
neuropathy (MMN), Guillain-Barré syndrome (GBS) and var-
iants, and CIDP. In CIDP with moderate to severe motor dis-
ability, IVIg is proven as the first-line immunotherapy,
including for maintenance treatment associated with immu-
nomodulatory drugs2,13,22. In GBS, similarly to the observed
effect of plasma exchange therapy, equal responses and
effects are observed with IVIg in the standard classical dose
of 400 mg/kg per day for 5 days. Its use as immunotherapy in
GBS remits to 1988. However, it is not established the
advantage of one method instead of the other in cases of
recurrence or no response if another course should be given
or plasma exchange performed2,22. In MMN, it is established
in different randomized controlled trials the first-line treat-
ment function of IVIg, using the same initial dose of GBS,
irrespective of the presence of positivity for anti-GM1 gang-
lioside antibody or conduction block2,22. Refractory cases or
partial responses are indicative of the possible use of immu-
nomodulatory drugs. In paraproteinaemic demyelinating
neuropathies, especially in cases of IgM monoclonal gammo-
pathy of undetermined significance, immunoglobulin use
represents the initial first-line treatment2.
In the case of motor neuron disease, there is no thera-
peutic improvement after high-dose intravenous immuno-
globulin use in amyotrophic lateral sclerosis28, although
moderate motor effects have been evinced in individual
cases of post-polio syndrome with rapid weakness and
amyotrophy progression2. Following the text the use of
immunoglobulin for inflammatory myopathies is discussed
in detail.
Clinical applications of immunoglobulin in
inflammatory myopathies
Inflammatory myopathies represent a wide group of
heterogeneous neuromuscular diseases, including mainly
acquired immune and infectious myopathies. The most
important clinical conditions include polymyositis, inclusion
body myositis and dermatomyositis. Several clinical and
pathological acquired variants, including paraneoplastic
and other myopathies related to autoimmune diseases, have
been described, however hereditary conditions are also
found. Specific pathological, clinical and currently radio-
logical criteria and findings are described in each of this con-
dition. In general, in summary, the treatment of most
autoimmune inflammatory forms depends on the use of oral
corticosteroids or maintenance pulse, in addition to any
combination with immunomodulators such as cyclosporine,
methotrexate and azathioprine29. It is exactly for cases in
which there is prolonged use of these therapies, in cases of
serious adverse events or in clinical refractory or partially
responsive disease that IVIg has been studied and applied.
The treatment of inflammatory myopathies with IVIg has
been mostly empirical. In recente years several open studies
have indicated a favorable effect mainly for dermatomyositis,
in which it has proved to increase clinical improvement and
muscle strength in cases of resistance to immunossupressive
and immunomodulatory drugs and in severe presentations,
generally in association with prednisone2. The same results
were less pronounced and evinced for polymyositis, in which
few studies showed the importance for reduction of corticos-
teroid dosage in chronic refractory disease, especially in
Table 3. Major groups of neurological diseases for which intravenous immunoglobulin has been studied in clinical trials, case
reports and currently used in practice2,18,21,22,23,24,25,26.
Intravenous immunoglobulin and groups of neurological diseases
Neuromuscular Diseases Inflammatory myopathies (dermatomyositis, polymyositis, inclusion body myositis – sporadic and
autosomal recessive hereditary type), neuromuscular junction disorders (myasthenia gravis class II/III
Osserman-Genkins classification, myasthenic crisis or exacerbation), peripheral neuropathy and
polyradiculoneuropathy (proximal subacute diabetic neuropathy, multifocal motor neuropathy,
Guillain-Barré syndrome and variants, Chronic inflammatory demyelinating polyneuropathy, critical
illness polyneuropathy and/or myopathy, autoimmune autonomic ganglionopathy), motor neuron disease
(post-Polio syndrome), others (complex regional pain syndrome type 1, formerly known as reflex
sympathetic dystrophy or Sudeck’s atrophy; resistant neuropathic pain)
Dementia and cognitive
disorders
Alzheimer’s disease, Mild cognitive impairment
Cerebellar ataxias Spinocerebellar ataxias, sporadic cerebellar ataxia (including the cerebellar predominant variant of
multiple system atrophy)
Demyelinating diseases Relapsing-remitting multiple sclerosis, acute disseminated encephalomyelitis, anti-aquaporin 4 antibody
positive neuromyelitis optica spectrum disorder, optic neuritis, chronic relapsing inflammatory optic
neuropathy (CRION)
Paraneoplastic neurological
disorders
Limbic encephalitis (anti-VGKC, anti-Hu, anti-Ma2, anti-CV2/CRMP5), subacute sensory neuronopathy
(anti-Hu, anti-CV2/CRMP5), opsoclonus-myoclonus (anti-Ri, anti-Hu, anti-Ma2, anti-amphiphysin),
cerebellar paraneoplastic degeneration (anti-Yo, anti-Hu, anti-Tr, anti-CV2/CRMP5, anti-VGCC), Lambert-Eaton
myastenic syndrome (anti-VGCC), peripheral nerve hyperexcitability in Isaacs’ syndrome (anti-VGKC)
Miscellaneous HIV-associated vacuolar myelopathy, Japanese encephalitis, Rasmussen encephalitis, refractory
autoimmune epilepsy with partial seizures, Stiff-person syndrome, PANDAS syndrome (pediatric
autoimmune neuropsychiatric disorders associated with streptococcal infections), ischaemic stroke,
Susac’s syndrome, narcolepsy
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cases without response to steroid immunosupressive treat-
ment2. In sporadic inclusion body myositis, it has been
proved that cases with severe dysphagia could benefit from
intravenous immunoglobulin, even though a formal recom-
mendation is still needed2,22,30,31,32. Although clinical response
was noticed in the cases described, molecular immune
mechanisms, activated immune cells and hystopathological
muscle changes were still equally represented before and
after immunoglobulin therapy33.
FINAL REMARKS
The use of intravenous immunoglobulin has been proven
effective in various situations within the neurological
practice, notably in neuromuscular diseases. Few rando-
mized multicenter clinical trials to study the effectiveness
of the drug in larger samples of patients have been made
for most diseases. Positive effects are demonstrated in open
studies in dermato- and polymyositis, myasthenia gravis, and
inflammatory neuropathies. Properly conducted randomized
clinical trials demonstrating the effect of IVIg are available in
GBS, CIDP, dermatomyositis, and smaller ones in multifocal
motor neuropathy. There is no doubt as to the necessity to
enhance the therapeutic role of this medication in neurological
diseases, especially in cases of severe disease or refractoriness
to the usual therapeutic modalities. It is also outstanding the
restricted indicators for use of IVIg in neurological disorders
in Brazil, limited to SGB, myasthenia gravis, juvenile dermato-
myositis, other dermatomyositis and polymyositis.
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